Antares Pharma To Host First Quarter Operating And Financial Results Conference Call
May 02 2016 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release
its first quarter 2016 financial results and recent operating
progress before the market opens on Monday, May 9, 2016, and host a
conference call shortly thereafter at 8:30 a.m. ET (Eastern
Time) to discuss the results. Robert F. Apple, President and Chief
Executive Officer will host the call.
Interested parties may participate in the
conference call by dialing 1-888-471-3843 (U.S.) or 1-719-325-2244
(international) 5 to 10 minutes prior to the start of the call. The
conference access code is 1348142. A replay of the conference
call will be available from 11:30 a.m. ET on Monday, May 9, 2016
through 11:30 a.m. ET on Tuesday, May 24, 2016 by dialing
1-888-203-1112 (U.S.) or 1-719-457-0820 (international), and
entering the access code 1348142. An audio web cast and
archive of the conference call will also be available under the
investor information section of the Antares Web site at
www.antarespharma.com.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP™
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. Antares
Pharma is also developing QuickShot® Testosterone for testosterone
replacement therapy, and has recently received a therapeutically
equivalent approval from the U.S. Food and Drug Administration for
VIBEX® Sumatriptan USP for the acute treatment of migraines.
The Company's technology platforms include VIBEX® disposable auto
injectors, disposable multi-use pen injectors and reusable
needle-free injectors. Antares Pharma has a multi-product deal with
Teva Pharmaceutical Industries, Ltd. that includes VIBEX®
epinephrine, exenatide multi-dose pen, and teriparatide multi-dose
pen. Our reusable needle-free injector for use with human
growth hormone (hGH) is sold worldwide by Ferring B.V. The
Company is also working with AMAG Pharmaceuticals on a subcutaneous
method of administering Makena, a progesterone product indicated
for use in lowering the risk of pre-term birth.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the outcome of the
pending patent litigation between Teva
Pharmaceutical Industries, Ltd. (Teva) and
Eli Lilly and Company regarding the Teriparatide
multi-dose pen; the timing and approval, if any, by the
U.S. Food and Drug Administration (FDA) of Teva’s
Abbreviated New Drug Application (ANDA) for
Teriparatide multi-dose pen and any future
revenue resulting therefrom; Teva’s ability to
adequately and timely respond to the Complete Response Letter
received from the FDA for the VIBEX® epinephrine pen ANDA and
approval by the FDA of the same, the timing and therapeutic
equivalence rating thereof, and any revenue pre or post FDA
approval; FDA action with respect to the ANDA filed for the
exenatide pen; the timing of the launch of VIBEX® Sumatriptan
Injection USP and the amount of revenue from the same, the timing
and results of the phase 3 studies for QuickShot® Testosterone (QS
T) and acceptance of the data by the FDA; the Company’s ability to
successfully complete a New Drug Application for QS T and submit to
the FDA and approval of the same by the FDA; continued growth of
prescriptions and sales of OTREXUP™; the timing and results
of research projects, clinical trials, and product candidates
in development; actions by the FDA or other regulatory agencies
with the respect to the Company’s products or product candidates of
its partners; continued growth in product, development, licensing
and royalty revenue; the Company’s ability to obtain financial and
other resources for its research, development, clinical, and
commercial activities and other statements regarding matters that
are not historical facts, and involve predictions. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance, achievements or
prospects to be materially different from any future results,
performance, achievements or prospects expressed in or implied by
such forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2015, and in
the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this press
release, except as required by law.
Contacts:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024